share_log

Clearmind Medicine | 20-F/A: Registration statement / Annual report / Transition report (Amendment)

Clearmind Medicine | 20-F/A: Registration statement / Annual report / Transition report (Amendment)

Clearmind Medicine | 20-F/A：年度報告/過渡報告/註冊聲明(修正)
SEC announcement ·  03/18 17:22
Moomoo AI 已提取核心信息
Clearmind Medicine Inc., a clinical-stage pharmaceutical company, has filed its annual financial report for the fiscal year ended October 31, 2023. The report details the company's financial position, business developments, and future plans. Financial Performance: Clearmind Medicine reported a net loss of $8,620,837 for the year, with comprehensive loss reflecting the same figure. The company has not generated any revenues and has a negative cash flow from operations of $6,301,472. The accumulated deficit as of October 31, 2023, stands at $18,768,063. Business Development: Clearmind Medicine is focused on the development of psychedelic medicines to address health problems. The company's research and development activities are primarily conducted in Israel. Future Plans: Clearmind Medicine plans to continue its clinical trials and research activities. The company has recently completed a public offering and expects to use the net proceeds to fund its operations and development plans. The company's financial statements have been prepared assuming the continuation of the business as a going concern.
Clearmind Medicine Inc., a clinical-stage pharmaceutical company, has filed its annual financial report for the fiscal year ended October 31, 2023. The report details the company's financial position, business developments, and future plans. Financial Performance: Clearmind Medicine reported a net loss of $8,620,837 for the year, with comprehensive loss reflecting the same figure. The company has not generated any revenues and has a negative cash flow from operations of $6,301,472. The accumulated deficit as of October 31, 2023, stands at $18,768,063. Business Development: Clearmind Medicine is focused on the development of psychedelic medicines to address health problems. The company's research and development activities are primarily conducted in Israel. Future Plans: Clearmind Medicine plans to continue its clinical trials and research activities. The company has recently completed a public offering and expects to use the net proceeds to fund its operations and development plans. The company's financial statements have been prepared assuming the continuation of the business as a going concern.
临床阶段的制药公司Clearmind Medicine Inc. 已提交了截至2023年10月31日的财年的年度财务报告。该报告详细介绍了公司的财务状况、业务发展和未来计划。财务业绩：Clearmind Medicine公布的年度净亏损为8,620,837美元，综合亏损反映了相同的数字。该公司没有产生任何收入，运营现金流为负6,301,472美元。截至2023年10月31日，累计赤字为18,768,063美元。业务发展：Clearmind Medicine专注于开发迷幻药物，以解决健康问题。该公司的研发活动主要在以色列进行。未来计划：Clearmind Medicine计划继续其临床试验和研究活动。该公司最近完成了公开募股，预计将使用净收益为其运营和发展计划提供资金。该公司的财务报表是在假设业务持续经营的情况下编制的。
临床阶段的制药公司Clearmind Medicine Inc. 已提交了截至2023年10月31日的财年的年度财务报告。该报告详细介绍了公司的财务状况、业务发展和未来计划。财务业绩：Clearmind Medicine公布的年度净亏损为8,620,837美元，综合亏损反映了相同的数字。该公司没有产生任何收入，运营现金流为负6,301,472美元。截至2023年10月31日，累计赤字为18,768,063美元。业务发展：Clearmind Medicine专注于开发迷幻药物，以解决健康问题。该公司的研发活动主要在以色列进行。未来计划：Clearmind Medicine计划继续其临床试验和研究活动。该公司最近完成了公开募股，预计将使用净收益为其运营和发展计划提供资金。该公司的财务报表是在假设业务持续经营的情况下编制的。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息